Multicentric clinical trials for safety and efficacy evaluation of alpha;beta arteether in complicated P. falciparum malaria.
OBJECTIVE
To evaluate efficacy of alpha;beta arteether in patients of P. falciparum malaria presenting with complications was undertaken in a multicentric clinical trial.


METHODS
Each patient who consented to undergo clinical trial with parenteral Arteether was treated with a fixed dose schedule of Arteether given intramuscularly in a dose of 150 mg once a day on three consecutive days. Every patient was followed upto 28 days with clinical, haematological and parasitological monitoring every day upto one week and thereafter at 14, 21 and 28 days. The response was assessed in terms of fever clearance time, parasite clearance time, cure rate and parasite reappearance rate.


RESULTS
A total of 211 patients of P. falciparum malaria were included in the study from four centres (Bhilai, Guwahati, Jamshedpur and Rourkela). Results of this study showed that fever clearance time ranged between 24-168 hours, parasite clearance time ranged between 24-120 hours and overall mortality ranged between 4-8.5%. Out of 211, only 14 patients expired during the study, of these, 10 patients expired within first two days i.e. before completing the three day schedule of arteether therapy. Tolerability to arteether injection was good in all these patients and no untoward effects were experienced or reported during the study. Overall cure rate observed in these studies was 93%.


CONCLUSIONS
This study shows a rapid parasite and fever clearance in patients of complicated P. falciparum malaria.
Asthana
O P
OP
Central Drug Research Institute, Lucknow.
Srivastava
J S
JS
Pandey
T K
TK
Vishwanathan
K A
KA
Dev
V
V
Mahapatra
K M
KM
Nayak
N C
NC
Balsara
A B
AB
Mandal
O P
OP
Gupta
N
N
Mishra
S K
SK
Mohanty
S
S
Sathpathy
S
S
Das
B S
BS
Patnaik
J K
JK
Sathpathy
S K
SK
Dash
B
B
D000293:Adolescent; D000328:Adult; D000818:Animals; D000962:Antimalarials / Q000009:adverse effects* / Q000627:therapeutic use*; D037621:Artemisinins; D005260:Female; D006801:Humans; D016778:Malaria, Falciparum / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010963:Plasmodium falciparum / Q000187:drug effects*; D011446:Prospective Studies; D012717:Sesquiterpenes / Q000009:adverse effects* / Q000627:therapeutic use*
D000962:Antimalarials; D037621:Artemisinins; D012717:Sesquiterpenes; C055141:artemotil